Outlook Therapeutics, Inc. (NasdaqCM: OTLK)
Health Care · Biotechnology · US
$0.59
+0.24% today · -55.3% 1Y
Outlook Therapeutics, Inc. (NasdaqCM: OTLK) operates in the Biotechnology industry within the Health Care sector. The company is valued at $142.44M and employs 17 people.
Over the last twelve months the share price has lost 55.3%, trading between 0.16 and 2.54.
Tweenvest scores Outlook Therapeutics, Inc. across four factors: quality 10/100, value 64/100. Its strongest factor is value.
OTLK price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $142.44M
- Revenue (TTM)
- $-1.16M
- P/E
- —
- EPS
- -0.75
- Dividend yield
- —
- Beta (5Y)
- 0.67
- 52-week high
- $2.54
- 52-week low
- $0.16
- Avg volume (3M)
- —
- Shares outstanding
- 243.45M
- Employees
- 17
- Next earnings
- —
About Outlook Therapeutics, Inc.
Outlook Therapeutics, Inc. is a biopharmaceutical company in the advanced stages of clinical development, focused on inventing and bringing to market monoclonal antibody treatments for various eye conditions. Its flagship drug candidate, ONS-5010, is an ophthalmic formulation of bevacizumab currently undergoing crucial Phase III clinical trials. This investigational product is being evaluated for its potential to treat wet age-related macular degeneration and other serious retinal diseases. The company has forged strategic collaboration and licensing agreements with several partners, including IPCA Laboratories Limited, Laboratorios Liomont, S.A. de C.V., BioLexis Pte. Ltd., and Zhejiang Huahai Pharmaceutical Co., Ltd. Incorporated in 2010, the firm was formerly known as Oncobiologics, Inc., changing its name to Outlook Therapeutics, Inc. in November 2018. Its corporate base is located in Iselin, New Jersey.
- ISIN
- US69012T3059
- Founded
- 2010
- Listed since
- Jun 14, 2016
- Exchange
- Nasdaq Capital Market
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| CANbridge Pharmaceuticals Inc.SEHK: 1228 | $145.79M | HK$1.92 | -6.59% |
| Kangstem Biotech Co., Ltd.KOSDAQ: A217730 | $144.47M | ₩2,065.00 | -7.81% |
| Atrium Therapeutics, Inc.NasdaqGS: RNA | $143.69M | $8.21 | -2.26% |
| UnicoCell Biomed Co., Ltd.TWSE: 6794 | $142.50M | NT$71.60 | -9.25% |
| Cloudbreak Pharma Inc.SEHK: 2592 | $140.32M | HK$— | — |
| Anavex Life Sciences Corp.NasdaqGS: AVXL | $139.97M | $1.51 | +1.34% |
| Voyager Therapeutics, Inc.NasdaqGS: VYGR | $139.87M | $2.27 | -7.35% |
| 3billion, Inc.KOSDAQ: A394800 | $139.66M | ₩5,900.00 | -2.32% |
Figures last refreshed Oct 11, 2026.